Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROTER Paracof is an over-the-counter (OTC) combination medication containing paracetamol (acetaminophen) and caffeine, marketed by the Dutch brand Roter (a subsidiary of Cooper Consumer Health). It is primarily used as an analgesic and antipyretic for the relief of mild to moderate pain, such as headache, muscle aches, and menstrual pain, as well as for reducing fever associated with the common cold or influenza. Paracetamol acts as a pain reliever and fever reducer, likely through the inhibition of prostaglandin synthesis in the central nervous system. Caffeine is included as an analgesic adjuvant to enhance the efficacy of paracetamol and provide a mild stimulant effect. Although the product is sometimes associated with cold and flu management (including the discomfort associated with coughing), it does not contain a direct antitussive agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + caffeine (Roter).